Drugs / IDE034
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | — | 2025-11-04 | “In the fourth quarter IDEAYA submitted an IND for IDE034 , a potential first-in-class B7H3/PTK7 bispecific TOP1i ADC” ideayabio.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07503808 | Feb 2026 → Jul 2027 expected | castration-resistant prostate carcinoma, colorectal cancer, endometrial cancer, esophageal squamous cell carcinoma +4 | IDEAYA Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-01-11 | IDEAYA Biosciences | Regulatory IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference ideayabio.com ↗
IDE574 (KAT6/7): obtained clearance of an IND application with the U.S. FDA in January 2026 |
| 2025-12-01 | IDEAYA Biosciences | Regulatory IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types ideayabio.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDE034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07503808 ↗ |